Fulgent Genetics, Inc. (FLGT)

Explore the exciting world of Fulgent Genetics (FLGT 2.11%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

While the stock price is unchanged since my buy rating a year ago, revenue growth is accelerating (FY25E: +14%) and gross margins are going up (FY25E: 40%, +200bps vs PY). Both precision diagnostics and anatomic pathology are positioned for sustainable double-digit revenue growth driven by innovation, increased insurance coverage, and geographic expansion. Meanwhile, Fulgent's Pharma segment continues to make steady progress, while cash burn remains moderate ($25 million in 2025).

Fulgent (FLGT) Q2 Revenue Jumps 16%

Friday's stock market was generally a gloomy place, but apparently someone forgot to tell Fulgent Genetics (FLGT 7.80%). The company's shares were soaring in late-session action, with a very healthy rise of more than 8%.

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Brandon Perthuis - Chief Commercial Officer Ming Hsieh - Chairman & CEO Paul Kim - Chief Financial Officer Conference Call Participants Andrew Harris Cooper - Raymond James & Associates, Inc., Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Lu Li - UBS Investment Bank, Research Division Lauren Sloane - The Blueshirt Group, LLC Operator Greetings, and welcome to the Fulgent Genetics Q2 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.23 per share. This compares to earnings of $0.15 per share a year ago.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2025. Second Quarter 2025 Results: Total Revenue of $81.8 million Core Revenue1 grew 16% year-over-year to $81.7 million GAAP loss of $19.0 million, or ($0.62) per share Non-GAAP income of $2.1 million,.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has received CE certification under the European Union (EU)'s In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) for its germline next-generation sequencing (NGS) system, which includes FulgentExome and Fulgent Pipeline Manager (PLM). Based on available i.

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer ques.

NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.